Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

NCT02419755 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Accrual goals were no longer feasible based on restrictions imposed by the DSMB.

Conditions

Mixed Lineage Acute Leukemia
Acute Myeloid Leukemia
Acute Lymphoid Leukemia

Interventions

DRUG: Bortezomib
DRUG: Vorinostat
DRUG: Mitoxantrone
DRUG: Cytarabine
DRUG: Methotrexate
DRUG: Hydrocortisone
DRUG: Peg-L-Asparaginase
DRUG: Erwinia L-Asparaginase
DRUG: Dexamethasone
DRUG: Mercaptopurine
DRUG: Doxorubicin

Sponsor

St. Jude Children's Research Hospital